DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
DURECT (DRRX), a late-stage biopharmaceutical company focused on epigenetic therapies targeting dysregulated DNA methylation, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 26, 2025.
The company will host a conference call and webcast with investors at 4:30 PM Eastern Time / 1:30 PM Pacific Time to discuss the financial results and provide a business update. Investors can access the event through guest dial-in numbers or use the Call me™ link for instant telephone access, which will be activated 15 minutes before the scheduled start time.
DURECT (DRRX), un'azienda biofarmaceutica in fase avanzata focalizzata su terapie epigenetiche che mirano a correggere la metilazione del DNA disfunzionale, ha programmato l'
L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta con gli investitori alle 4:30 PM Eastern Time / 1:30 PM Pacific Time per discutere i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori possono accedere all'evento tramite numeri di accesso per ospiti o utilizzare il link Call me™ per un accesso telefonico immediato, che sarà attivato 15 minuti prima dell'orario di inizio programmato.
DURECT (DRRX), una empresa biofarmacéutica en fase avanzada centrada en terapias epigenéticas que abordan la metilación del ADN desregulada, ha programado el anuncio de resultados financieros del cuarto trimestre y del año completo 2024 para el miércoles 26 de marzo de 2025.
La empresa llevará a cabo una llamada de conferencia y una transmisión web con inversores a las 4:30 PM Eastern Time / 1:30 PM Pacific Time para discutir los resultados financieros y proporcionar una actualización empresarial. Los inversores pueden acceder al evento a través de números de acceso para invitados o utilizar el enlace Call me™ para acceso telefónico instantáneo, que se activará 15 minutos antes de la hora de inicio programada.
DURECT (DRRX), 비정상적인 DNA 메틸화를 목표로 하는 후반 단계의 에피제네틱 치료에 중점을 둔 생명공학 회사는 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 26일 수요일로 예정했습니다.
회사는 동부 표준시 오후 4:30 / 태평양 표준시 오후 1:30에 투자자와 함께 재무 결과를 논의하고 비즈니스 업데이트를 제공하기 위한 컨퍼런스 콜 및 웹캐스트를 개최합니다. 투자자는 게스트 다이얼인 번호를 통해 이벤트에 접근하거나 Call me™ 링크를 사용하여 즉각적인 전화 접근을 할 수 있으며, 이는 예정된 시작 시간 15분 전에 활성화됩니다.
DURECT (DRRX), une entreprise biopharmaceutique en phase avancée axée sur des thérapies épigénétiques ciblant la méthylation de l'ADN déséquilibrée, a programmé son annonce des résultats financiers du quatrième trimestre et de l'année complète 2024 pour le mercredi 26 mars 2025.
L'entreprise organisera une conférence téléphonique et un webinaire avec les investisseurs à 16h30, heure de l'Est / 13h30, heure du Pacifique pour discuter des résultats financiers et fournir une mise à jour sur les activités. Les investisseurs peuvent accéder à l'événement via des numéros de connexion invités ou utiliser le lien Call me™ pour un accès téléphonique instantané, qui sera activé 15 minutes avant l'heure de début prévue.
DURECT (DRRX), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf epigenetische Therapien zur Bekämpfung von dysregulierter DNA-Methylierung konzentriert, hat die Ankündigung der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Mittwoch, den 26. März 2025, angesetzt.
Das Unternehmen wird um 16:30 Uhr Eastern Time / 13:30 Uhr Pacific Time eine Telefonkonferenz und ein Webcast mit Investoren veranstalten, um die finanziellen Ergebnisse zu erörtern und ein Unternehmensupdate bereitzustellen. Investoren können über Gastzugangsnummern auf die Veranstaltung zugreifen oder den Link Call me™ für einen sofortigen Telefonzugang nutzen, der 15 Minuten vor der geplanten Startzeit aktiviert wird.
- None.
- None.
Wednesday, March 26th @ 4:30 pm Eastern Time / 1:30 pm Pacific Time
Toll Free: | 1-877-407-0784 |
International | 1-201-689-8560 |
Conference ID | 13752005 |
Call Me: | https://callme.viavid.com/viavid/?callme=true&passcode=13740526&h=true&info=company-email&r=true&B=6 |
Participants can use guest dial-in numbers above to reach an operator or they can click the Call me™ link for instant telephone access to the event (dial-out). The Call me™ link will be made active 15 minutes prior to the scheduled start time.
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1709648&tp_key=7b0e755edd
About DURECT Corporation
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Breakthrough Therapy designation; MASH is also being explored. In addition, POSIMIR®(bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved. For more information about DURECT, please visit www.durect.com and follow us on X (formerly Twitter) at https://x.com/DURECTCorp.
DURECT Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our plans to report fourth quarter and full year 2024 financial results on March 26, 2025 and the potential uses of larsucosterol to treat patients with AH and potentially other indications. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risk that future clinical trials of larsucosterol are delayed or do not confirm the results from subset analyses of the AHFIRM trial, including geographic or other segmentation, or of earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner; the risk that we do not raise sufficient capital to commence or complete the Phase 3 clinical trial of larsucosterol in patients with AH or continue to fund our operations, the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving larsucosterol for the treatment of AH, the risk that Breakthrough Therapy designation does not expedite the process for FDA approval and that larsucosterol may never be approved; and risks related to the sufficiency of our cash resources, our anticipated capital requirements, our ability to meet the minimum bid price for continued listing on Nasdaq, and our ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission (SEC) filings, including its annual report on Form 10-K for the year ended December 31, 2024, when filed, under the heading "Risk Factors." These reports are available on our website www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov. All information provided in this press release and in the attachments is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-business-update-302406328.html
SOURCE DURECT Corporation
FAQ
When will DURECT (DRRX) release Q4 and full year 2024 earnings?
What time is DRRX's Q4 2024 earnings call scheduled for?
How can investors access DRRX's Q4 2024 earnings call?
What is DURECT 's main business focus?
